Chimeric antigen receptor T cells for sustained remissions in leukemia.

ABSTRACT:

Background

Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.

Methods

We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76×10(6) to 20.6×10(6) CTL019 cells per kilogram of body weight. Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells.

Results

A total of 30 children and adults received CTL019. Complete remission was achieved in 27 patients (90%),

SUBMITTER: Maude SL 

PROVIDER: S-EPMC4267531 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature